Deepak Dalvie

A holistic strategy for characterizing the safety of metabolites through drug discovery and development.

Don Walker, Joe Brady, Deepak Dalvie, 2009, Chemical research in toxicology.

Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites.

Deepak Dalvie, Angus Nedderman, R Scott Obach, 2009, Chemical research in toxicology.

Aldehyde oxidase: an enzyme of emerging importance in drug discovery.

Deepak Dalvie, R Scott Obach, R. Obach, 2010, Journal of medicinal chemistry.

Pathways of Reactive Metabolite Formation with Toxicophores/‐Structural Alerts

Deepak Dalvie, Amit S. Kalgutkar, A. Kalgutkar, 2012 .

Predicting toxicities of reactive metabolite-positive drug candidates.

Deepak Dalvie, Amit S. Kalgutkar, A. Kalgutkar, 2015, Annual review of pharmacology and toxicology.

Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.

Deepak Dalvie, Michael Zientek, Rose Ann Ferre, 2016, Journal of medicinal chemistry.

Strategies for a comprehensive understanding of metabolism by aldehyde oxidase

Deepak Dalvie, R. Obach, D. Dalvie, 2013, Expert opinion on drug metabolism & toxicology.

Abstract 4863: PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors

Paolo Vicini, Deepak Dalvie, Chad Ray, 2016 .

Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.

Paolo Vicini, Deepak Dalvie, Chengyi Zhang, 2017, Journal of medicinal chemistry.